ArticleThe journal of headache and pain2019
Burden and costs of migraine in a Swedish defined patient population - a questionnaire-based study.
Article in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Migraine in the Corporate Sector: Prevalence, Risk Factors, Job Efficiency Impact, and Management Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United Kingdom.Therapeutics and clinical risk management · 2026Article
- Migraine Prevalence and QALY Loss in Serbia: A Population-Level Stratified Modeling Study.Risk management and healthcare policy · 2026Article
- Real-world adherence to erenumab, rescue medication utilization, and work absenteeism for patients with migraine: Results from an outcomes-based agreement.Journal of managed care & specialty pharmacy · 2025Article
- Unveiling the Public Economic Burden of Migraine in Argentina.Journal of health economics and outcomes research · 2025Article
- A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy.BMC neurology · 2024Article
- Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study.The journal of headache and pain · 2024Article
- Healthcare resource utilization and associated costs among patients with migraine in Finland: A retrospective register-based study.PloS one · 2024Observational
- Evaluating the Impact of a Training Program in Shared Decision-Making for Neurologists Treating People with Migraine.Neurology and therapy · 2023Article
- The Hidden Economic Consequences of Migraine to the UK Government: Burden-of-Disease Analysis Using a Fiscal Framework.Journal of health economics and outcomes research · 2023Article
- Headache in Workers: A Matched Case-Control Study.European journal of investigation in health, psychology and education · 2022Article
- The remarkably frequent use of EQ-5D in non-economic research.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Headache in the Workplace: Analysis of Factors Influencing Headaches in Terms of Productivity and Health.International journal of environmental research and public health · 2022Article
- Prevalence of Migraine in General Spanish Population; Factors Related and Use of Health Resources.International journal of environmental research and public health · 2021Article
- Article
- Advantages of imaging photoplethysmography for migraine modeling: new optical markers of trigemino-vascular activation in rats.The journal of headache and pain · 2021Article
- Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.PharmacoEconomics · 2021Article
- Analysis of treatment cost and persistence among migraineurs: A two-year retrospective cohort study in Pakistan.PloS one · 2021Article
- Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability.International journal of environmental research and public health · 2020Review
- My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland.The journal of headache and pain · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine is a disabling, chronic neurological disease leading to severe headache episodes affecting 13.2% of the Swedish population. Migraine leads to an extensive socio-economic burden in terms of healthcare costs, reduced workforce and quality of life (QoL) but studies of the health-economic consequences in a Swedish context are lacking. The objective of this study is to map the health-economic consequences of migraine in a defined patient population in terms of healthcare consumption, production loss and QoL in Sweden.
methodsThe study is based on data from a web-based survey to members in the Swedish patients' association suffering from migraine. The survey was conducted in May 2018 and included people with migraine aged 18 years or older. The survey included questions on health resource consumption, lost production resulting from migraine-related absenteeism and presenteeism, and QoL as measured by the EuroQol 5 dimensions questionnaire (EQ-5D-5 L) and the Headache Impact Test (HIT-6). The results are presented in yearly costs per patient and losses in quality adjusted life years (QALYs).
resultsThe results are based on answers from 630 individuals with migraine and are presented by number of migraine days per month. The total cost per patient and year increased with the number of migraine days per month (p < 0.001) and varied between approximately €5000 for those with less than 3 migraine days per month and €24,000 per year for those with 21-28 migraine days per month. Production loss represented the main part of the costs, approximately 80%. The average loss in QALYs per year also increased with the monthly number of migraine days (p = 0.023).
conclusionsMigraine leads to significant societal costs and loss of quality of life. There appears to be an unmet need and a potential for both cost savings and QoL benefits connected with a reduction in the number of migraine days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.